Carbidopa Tablet
NDC 43386-980
Product Information
Carbidopa is a ANDA-approved product labeled by Lupin Pharmaceuticals,inc.. This medication is used with a combination levodopa/carbidopa product to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). It is supplied as a orange tablet for oral administration. This product entry covers the primary NDC 43386-980 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
NL;C
Code Structure Chart
Product Details
What is NDC 43386-980?
What are the uses of this product?
What are Active Ingredients of this product?
- CARBIDOPA 25 mg/1 - An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CARBIDOPA (UNII: MNX7R8C5VO)
- CARBIDOPA ANHYDROUS (UNII: KR87B45RGH) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- STARCH, CORN (UNII: O8232NY3SJ)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 260260 - carbidopa 25 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.
Patient Education
Levodopa and Carbidopa
The combination of levodopa and carbidopa is used to treat the symptoms of Parkinson's disease and Parkinson's-like symptoms that may develop after encephalitis (swelling of the brain) or injury to the nervous system caused by carbon monoxide poisoning or manganese poisoning. Parkinson's symptoms, including tremors (shaking), stiffness, and slowness of movement, are caused by a lack of dopamine, a natural substance usually found in the brain. Levodopa is in a class of medications called central nervous system agents. It works by being converted to dopamine in the brain. Carbidopa is in a class of medications called decarboxylase inhibitors. It works by preventing levodopa from being broken down before it reaches the brain. This allows for a lower dose of levodopa, which causes less nausea and vomiting.
[Learn More]
* Please review the full disclaimer at the bottom of this page.